Translation Enhancing Therapeutics

About us

TranSINE^TM Therapeutics, is a new, rapidly evolving biotech based in the research hub of Cambridge, UK, that is focused on the development of SINEUPs^TM, a revolutionary platform technology that specifically increases the translation of target proteins in a fully plug-and-play manner. This unique and scalable platform enables TranSINE^TM to address unmet medical needs and build differentiated products that cannot be generated with other technologies.

TranSINE^TM Therapeutics has world class founders, Professor Stefano Gustincich and Professor Piero Carninci, pioneers in the fields of functional genomics and transcriptomics. The identification of SINEUPs^TM, a novel class of long non-coding RNAs, was first reported in Carrieri et al., Nature. 2012;491(7424):454-457. In 2020, the value of this ground-breaking new therapeutic class was realized when TranSINE^TM Therapeutics received significant seed funding from Takeda Ventures Inc. and the Dementia Discovery Fund to build a pipeline of novel therapeutics across multiple disease areas including ophthalmology and neurology.

Current vacancies

TranSINE^TM Therapeutics is evolving fast. With the development of the TranSINE^TM Therapeutics Labs at the Babraham Research Campus, we are currently recruiting for:

Research Scientist/Senior Scientist